Combined oral contraceptives in women with systemic lupus erythematosus.

By M. Petri, Mimi Y. Kim, K. Kalunian, J. Grossman, B. Hahn, L. Sammaritano, M. Lockshin, J. Merrill, H. Belmont, A. Askanase and 15 more. New England Journal of Medicine, 2005

1,113 citations recorded by the source corpus.

Subfields: Reproductive Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/cd5c8e37673576be805a8850285c7f55a15adbc3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. J. Smolen

Citations in the corpus

• EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (2007, background): “Although oestrogen use has been associated with increased risk for developing SLE,(66) two RCTs have concluded that oral oestrogen contraceptives do not increase the risk for flare in stable disease.(67) 68 Hormone-replacement therapy results in a significantly better change in bone mass density com”
• EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome (2015, background): “63 64 In women with positive aPL ( with or without de fi nite APS ), contraception with combined hormones (oral pill, vaginal ring, transdermal patch) should be discouraged.”